Adjuvant chemotherapy for node negative, high Recurrence ScoreTM breast cancer: in defense of de-escalation
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology
Link
http://www.nature.com/articles/s41523-019-0119-5.pdf
Reference36 articles.
1. Jatoi, I., Benson, J. R. & Toi, M. De-escalation of axillary surgery in early breast cancer. Lancet Oncol. 17, e430–e441 (2016).
2. Yao, K. & Boughey, J. C. “Nudging” surgeons and patients to de-escalation of surgery for breast cancer. Ann. Surg. Oncol. 25, 2777–2780 (2018).
3. Houvenaeghel, G. et al. Therapeutic escalation/de-escalation: Data from 15,508 early breast cancer treated with upfront surgery and sentinel lymph node biopsy (SNLB). Breast 34, 24–33 (2017).
4. Franco, P. et al. De-escalation of breast radiotherapy after conserving surgery in low-risk early breast cancer patients. Med Oncol. 35, 62 (2018).
5. Harbeck, N. et al. De-Escalation strategies in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (BC): final analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial: Efficacy, safety, and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy (ET) versus trastuzumab plus ET. J. Clin. Oncol. 35, 3046–3054 (2017).
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Family Engagement in Schools: Parent, Educator, and Community Perspectives;SAGE Open;2020-10
2. INFLUENCE OF BECLIN 1 ON SENSITIVITY OF TAMOXIFEN OF OESTROGEN-RECEPTOR-POSITIVE BREAST CANCER BY REGULATING HER2 EXPRESSION LEVEL;ACTA MEDICA MEDITERR;2020
3. A Rational Approach to a De-Escalation of Double Antithrombotic Therapy: The Possibilities of Clopidogrel;Medical Council;2019-10-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3